Raymond James Financial Services Advisors Inc. Sells 12,361 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Raymond James Financial Services Advisors Inc. reduced its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 16.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,040 shares of the biopharmaceutical company’s stock after selling 12,361 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.08% of Ocular Therapeutix worth $277,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Raymond James & Associates increased its holdings in shares of Ocular Therapeutix by 7.0% in the fourth quarter. Raymond James & Associates now owns 129,012 shares of the biopharmaceutical company’s stock worth $575,000 after acquiring an additional 8,451 shares in the last quarter. Legato Capital Management LLC bought a new stake in shares of Ocular Therapeutix in the fourth quarter worth about $667,000. SG Americas Securities LLC increased its holdings in shares of Ocular Therapeutix by 60.5% in the fourth quarter. SG Americas Securities LLC now owns 19,646 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 7,404 shares in the last quarter. Graham Capital Management L.P. bought a new stake in shares of Ocular Therapeutix in the third quarter worth about $299,000. Finally, GSA Capital Partners LLP increased its holdings in shares of Ocular Therapeutix by 96.4% in the third quarter. GSA Capital Partners LLP now owns 233,582 shares of the biopharmaceutical company’s stock worth $733,000 after acquiring an additional 114,629 shares in the last quarter. 59.21% of the stock is currently owned by institutional investors.

Insider Activity at Ocular Therapeutix

In related news, insider Rabia Gurses Ozden sold 7,764 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total transaction of $38,431.80. Following the completion of the transaction, the insider now directly owns 92,767 shares of the company’s stock, valued at $459,196.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Rabia Gurses Ozden sold 7,764 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total value of $38,431.80. Following the completion of the sale, the insider now directly owns 92,767 shares of the company’s stock, valued at $459,196.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Philip C. Strassburger sold 6,831 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total value of $33,813.45. Following the completion of the sale, the general counsel now directly owns 109,218 shares of the company’s stock, valued at $540,629.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,366 shares of company stock valued at $194,862. Insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Bank of America assumed coverage on Ocular Therapeutix in a report on Friday, February 9th. They set a “buy” rating and a $15.00 price objective for the company. StockNews.com downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Friday, April 5th. Piper Sandler increased their price objective on Ocular Therapeutix from $10.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, February 26th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Ocular Therapeutix in a report on Friday. Finally, JMP Securities reiterated a “market outperform” rating and set a $24.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, April 16th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.60.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL opened at $5.08 on Tuesday. The stock has a 50 day moving average price of $8.73 and a 200 day moving average price of $5.36. Ocular Therapeutix, Inc. has a 52 week low of $2.00 and a 52 week high of $11.31. The company has a debt-to-equity ratio of 0.82, a quick ratio of 6.59 and a current ratio of 6.66. The stock has a market capitalization of $754.30 million, a PE ratio of -4.06 and a beta of 1.31.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). Ocular Therapeutix had a negative return on equity of 321.12% and a negative net margin of 138.15%. The firm had revenue of $14.80 million during the quarter, compared to analysts’ expectations of $15.31 million. Analysts predict that Ocular Therapeutix, Inc. will post -0.68 earnings per share for the current fiscal year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.